These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16421596)

  • 1. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
    Barnes N; Haywood P; Flint P; Knox WF; Bundred NJ
    Br J Cancer; 2006 Jan; 94(2):253-8. PubMed ID: 16421596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
    Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
    Oliveira VM; Piato S; Silva MA
    Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
    Ranger GS; Jewell A; Thomas V; Mokbel K
    J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin expression predicts early recurrence in early-stage breast cancer.
    Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
    Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
    Leo C; Faber S; Hentschel B; Höckel M; Horn LC
    Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordant loss of fragile gene expression early in breast cancer development.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
    Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
    Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
    de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
    Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situ.
    Baltayan A; Naritoku WY; Chaiwun B; Tsao-Wei DD; Groshen S; Hern RA; Gusterson BA; Taylor CR; Imam SA
    Anticancer Res; 2002; 22(5):2933-7. PubMed ID: 12530020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
    Erkanli S; Bolat F; Kayaselcuk F; Demirhan B; Kuscu E
    Gynecol Oncol; 2007 Feb; 104(2):320-5. PubMed ID: 17030351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.